# A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.

> **NCT00629876** · PHASE1 · TERMINATED · sponsor: **Takeda** · enrollment: 2 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** Peginesatide

## Key facts

- **NCT ID:** NCT00629876
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Due to the uncertain regulatory landscape for erythropoiesis-stimulating agents in oncology indications.
- **Last updated:** 2011-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00629876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00629876, "A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00629876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*